Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 15/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185729 | 0.83 | NPSR1 (0.45) | PKMNPY5R | |
| SCHEMBL84377 | 0.83 | KDM4D (0.45) | PKMNPY5RCHRNA7HRH4 | |
| SCHEMBL84072 | 0.76 | PKM (0.50) | PKM | |
| SCHEMBL84398 | 0.73 | ACACB (0.42) | HTR3AHRH4 | |
| SCHEMBL84471 | 0.73 | HRH4 (0.51) | HTR3AHRH4 | |
| SCHEMBL12986127 | 0.72 | CXCR4 (0.50) | HTR3AHRH4 | |
| SCHEMBL84065 | 0.72 | MAPK9 (0.48) | HRH4 | |
| SCHEMBL84366 | 0.72 | CYP1A2 (0.44) | HRH4 | |
| SCHEMBL13384588 | 0.71 | HRH4 (0.52) | HRH4 | |
| SCHEMBL83989 | 0.70 | HRH4 (0.36) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CTPS1 708/4885PKM 1907/4885NPY5R 4815/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CTPS1 918/4885PKM 1298/4885NPY5R 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.